Objectives: The objective of this study is to identify risk factors for hypersensitivity reaction (HSR) to tocilizumab (TCZ) in systemic juvenile idiopathic arthritis (sJIA).
Methods: Clinical records of 40 patients with sJIA administered TCZ at one center were retrospectively reviewed. Patients were divided into HSR or non-HSR groups depending on the presence of HSR between the first and third TCZ administrations; clinical and laboratory assessments, including serum cytokine profile, were compared.
Results: Five patients displayed HSR following the third TCZ administration. They were significantly younger, shorter, and lighter, with a higher peak body temperature than non-HSR patients following the third administration. Their serum C-reactive protein (CRP) level was undetectable following the first administration but detectable by the third administration. Before the third administration, the white blood cell counts and serum levels of CRP and sTNFRII were significantly higher in the HSR group than in the non-HSR group. The serum levels of interleukin-18 and -6 before the third TCZ administration were higher and lower than those before the first administration in the HSR and non-HSR groups, respectively.
Conclusion: Patients with sJIA having a younger age, shorter stature, and lighter weight and those showing increased disease activity in the early period of TCZ administration may be at higher risk of TCZ-induced HSR.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14397595.2018.1457490 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Does tocilizumab eliminate inflammation in GCA? A cohort study on repeated temporal artery biopsies.
RMD Open
December 2024
Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background: Vascular inflammation persists in temporal artery biopsy (TAB) of giant cell arteritis (GCA) patients even after prolonged glucocorticoid (GC) therapy. We aimed to evaluate the histological impact of adding tocilizumab (TCZ) to GCs.
Methods: We enrolled all consecutive GCA patients with an inflammed TAB at diagnosis who were treated with TCZ and GCs for ≥6 months and followed from December 2017 to December 2023.
Efficacy and safety of tocilizumab treatment in refractory MOG-IgG related optic neuritis.
Ther Adv Neurol Disord
December 2024
Department of Ophthalmology, The Third Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China.
Background: Myelin oligodendrocyte glycoprotein (MOG) IgG related optic neuritis (ON) which manifests as recurrent episodes and severe visual impairment remains a challenging issue in relapse prevention. Tocilizumab (TCZ), a human monoclonal antibody against IL-6R, may be an alternative treatment for the prevention of relapse in refractory MOG-ON patients.
Objectives: To investigate the efficacy and safety of Tocilizumab (TCZ) in patients with recurrent myelin oligodendrocyte glycoprotein IgG related optic neuritis (MOG-ON).
Transformed follicular lymphoma with laryngeal edema requiring tracheal intubation after tisagenlecleucel treatment: A case report.
Medicine (Baltimore)
September 2024
Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
Article Synopsis
- Cytokine release syndrome (CRS) is a common side effect of CAR-T cell therapy, which can sometimes manifest as localized CRS (L-CRS) affecting specific areas like the larynx.
- A 67-year-old woman with transformed follicular lymphoma experienced laryngeal edema after CAR-T treatment, requiring tracheal intubation due to inadequate response to standard treatments (tocilizumab and dexamethasone).
- Key takeaways include recognizing that CAR-T therapy can lead to serious L-CRS like laryngeal edema, that TCZ alone may not be effective for cervical L-CRS, and the importance of prompt management to prevent airway complications.
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).
Arthritis Res Ther
September 2024
Department of Rheumatology and Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China.
Article Synopsis
- The study investigated the efficacy and safety of the biosimilar BAT1806/BIIB800 compared to the reference drug tocilizumab (TCZ) in patients with moderate-to-severe rheumatoid arthritis over a treatment period of 24-48 weeks.
- Results showed that the effectiveness of both treatments was similar, with high response rates (ACR20), along with comparable safety and immunogenicity profiles across treatment groups.
- Overall, the study concluded that BAT1806/BIIB800 has similar therapeutic outcomes to TCZ, supporting its use as a treatment option for rheumatoid arthritis patients.
Taper versus discontinuation of tocilizumab in patients with giant cell arteritis: Real-world experience from a tertiary center.
Semin Arthritis Rheum
October 2024
Aarhus University Hospital, Department of Rheumatology, Aarhus, Denmark; Aarhus University, Department of Clinical Medicine, Aarhus, Denmark.
Introduction: Following the approval of tocilizumab (TCZ) for giant cell arteritis (GCA), recent studies have shown a high relapse frequency after abrupt discontinuation of TCZ. However, a thorough exploration of TCZ tapering compared to abrupt discontinuation has never been undertaken. Likewise, adverse events have only been scarcely investigated in routine care.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!